Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Context Therapeutics Q2 EPS $(0.25)

Context Therapeutics Q2 EPS $(0.25)

Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.25) per share.

August 11, 2022

1 minute read

Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.25) per share.

Morgan Stanley Maintains Equal-Weight on Sportradar Gr, Lowers Price Target to $11

March 16, 7:38 AM

Morgan Stanley analyst Stephen Grambling maintains Sportradar Gr (NASDAQ:SRAD) with a Equal-Weight and lowers the price target from $11.5 to $11.

December 19, 7:37 AM

DoD Issues $24.8M Critical Minerals Award to Perpetua Resources > U.S. Department of Defense > Release

January 19, 10:34 AM

Bloomberg

October 13, 7:23 AM

B of A Securities analyst Shaun Kelley upgrades Las Vegas Sands (NYSE:LVS) from Underperform to Neutral and announces $37 price target.